English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

A randomized‐controlled trial to evaluate the app‐based multimodal weight loss programzanadiofor patients with obesity

MPS-Authors
/persons/resource/persons277699

Roth,  Lena
Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Finland;
Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society;
aidhere GmbH, Hamburg, Germany;

/persons/resource/persons19734

Horstmann,  Annette       
Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Finland;
Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society;
Faculty of Medicine, University of Leipzig, Germany;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

Roth_2023.pdf
(Publisher version), 3MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Roth, L., Ordnung, M., Forkmann, K., Mehl, N., & Horstmann, A. (2023). A randomized‐controlled trial to evaluate the app‐based multimodal weight loss programzanadiofor patients with obesity. Obesity, 31(5), 1300-1310. doi:10.1002/oby.23744.


Cite as: https://hdl.handle.net/21.11116/0000-000D-0DB8-6
Abstract
Objective
This study aimed to evaluate the effectiveness of the app-based, multimodal weight loss program zanadio.

Methods
A randomized-controlled trial was conducted from January 2021 to March 2022. A total of 150 adults with obesity were randomized into an intervention group and used zanadio for 1 year or into a wait list control group. The primary end point, weight change, and the secondary end points, quality of life, well-being, and waist to height ratio, were assessed every 3 months for up to 1 year via telephone interviews and online questionnaires.

Results
After 12 months, participants of the intervention group lost, on average, −7.75% (95% CI: −9.66% to −5.84%) of their initial weight, achieving a clinically relevant and statistically stronger weight reduction than the control group (mean = 0.00% [95% CI: −1.98% to 1.99%]). All secondary end points improved significantly in the intervention group, with significantly greater improvements in well-being and waist to height ratio than in the control group.

Conclusions
This study showed that adults with obesity who have used zanadio achieved a significant and clinically relevant weight loss within 12 months and improved further obesity-related health variables compared with a control group. Because of its effectiveness and flexible applicability, the app-based multimodal treatment zanadio might alleviate the present care gap for patients with obesity in Germany.